Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for maintenance of arteriovenous hemodialysis graft patency
IRCT20231108059994N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in Arteriovenous Graft Occlusion and chronic kidney disease (CKD) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Artificial vein thrombosis rate at 1 month, Artificial vein thrombosis rate at 3 months and 1 more. Started Mar 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Arteriovenous Graft Occlusionchronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20231108059994N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231108059994N1.